Skip to main content

BioCardia, Inc.

corporate_fare Company Profile

BioCardia, Inc.

BCDA·NASDAQ·Life Sciences·CIK 0000925741

We are a clinical-stage company focused on developing cellular and cell-derived therapies for cardiovascular and pulmonary diseases. Our primary platform is the CardiAMP® autologous mononuclear cell therapy, which is in clinical development for two cardiac conditions: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina due to chronic myocardial ischemia (CMI). This platform targets microvascular dysfunction, aiming to enhance microvascular density and reduce fibrosis. We also have an allogeneic mesenchymal stem cell (MSC) therapy platform, an "off the shelf" cell therapy, in clinical development for ischemic inflammatory HFrEF, based on its immunomodulatory mechanism. While our investigational new drug (IND) for these same cells in acute respiratory distress syndrome has been approved by the FDA, this program has not yet advanced clinically. Our Helix™ transendocardial biotherapeutic delivery system facilitates minimally invasive catheter-based intramyocardial therapeutic delivery for our cardiac candidates. We also partner this delivery platform and offer development services to other companies developing biotherapeutic interventions for local heart delivery. Heart failure, a condition where the heart's blood output is insufficient, affected nearly 6.7 million American adults aged 20 and older in 2024, according to the American Heart Association (AHA). The AHA projects a 55% increase in heart failure prevalence from 2012 to 2030, impacting over 8.5 million people aged 18 and above. The total percentage of the population with HF is projected to rise from 2.4% in 2012 to 3.0% in 2030, with 47% of the effective population estimated to have HFrEF. In 2012, heart failure cost the nation an estimated $30.7 billion.

BioCardia, Inc. (NASDAQ:BCDA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 32 items for BCDA at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • BioCardia Secures Key Japanese Patent for Heart3D™ Imaging Software
  • BioCardia's CardiAMP Cell Therapy Nears Japan Market Clearance with Positive PMDA Consultation
  • Nasdaq Notifies BioCardia of Listing Non-Compliance, Citing Equity Shortfall
  • BioCardia Receives Formal Nasdaq Delisting Non-Compliance Notice
  • BioCardia Submits CardiAMP HF Data to FDA, Seeks Accelerated Approval Pathway Meeting

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$0
Net Income
-$8.23M
Op. Cash Flow
-$7.44M
Free Cash Flow
-$7.44M
Operating Income
-$8.28M
Cash & Equivalents
$2.5M
Debt / Equity
0.00×
Shares Outstanding
10.76M sh
Source: 10-K · filed 2026-03-24 · accession 0001437749-26-009587
$0.75 -4.46% today
52-week range · as of 2026-11-20 $0.661 – $1.8
Market cap
$11.88M
Volume
352.4K (2.9× avg)
3-mo avg 120.9K
Live data · 2026-11-22 12:45 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed BCDA - Filings & News (Page 2)

BCDA
Apr 28, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.19
Real-time Price: $0.750 info
Change: -$0.440 (-37%) info
Market Cap: $11.884M info
BCDA
Apr 20, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.20
Real-time Price: $0.750 info
Change: -$0.450 (-38%) info
Market Cap: $11.884M info
BCDA
Apr 15, 2026, 4:33 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $1.18
Real-time Price: $0.750 info
Change: -$0.4301 (-36%) info
Market Cap: $11.884M info
BCDA
Apr 15, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.18
Real-time Price: $0.750 info
Change: -$0.4301 (-36%) info
Market Cap: $11.884M info
BCDA
Apr 02, 2026, 9:00 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.16
Real-time Price: $0.750 info
Change: -$0.410 (-35%) info
Market Cap: $11.884M info
BCDA
Mar 24, 2026, 4:05 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $1.12
Real-time Price: $0.750 info
Change: -$0.3701 (-33%) info
Market Cap: $11.884M info
BCDA
Mar 17, 2026, 6:02 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.39
Real-time Price: $0.750 info
Change: -$0.640 (-46%) info
Market Cap: $11.884M info
BCDA
Mar 17, 2026, 6:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.28
Real-time Price: $0.750 info
Change: -$0.529 (-41%) info
Market Cap: $11.884M info
BCDA
Mar 03, 2026, 8:03 AM EST
Source: Wiseek News
Importance Score:
9
Price at Filing: $1.37
Real-time Price: $0.750 info
Change: -$0.620 (-45%) info
Market Cap: $11.884M info
BCDA
Mar 03, 2026, 8:01 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.37
Real-time Price: $0.750 info
Change: -$0.620 (-45%) info
Market Cap: $11.884M info
BCDA
Feb 10, 2026, 9:15 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.27
Real-time Price: $0.750 info
Change: -$0.520 (-41%) info
Market Cap: $11.884M info
BCDA
Feb 03, 2026, 8:00 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.20
Real-time Price: $0.750 info
Change: -$0.450 (-38%) info
Market Cap: $11.884M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets